The National Comprehensive Cancer Network has announced the development of another "price" calculator that will help stakeholders assess the relative "value" of available options.
The past few months have seen reports of new tools being offered—and resistance being voiced—for cancer drug costs. The participants are physicians who treat cancer patients and are increasingly seeing their and their patients’ hands being tied by the expense associated with these drug costs. Now, to complement the DrugAbacus tool developed at the Memorial Sloan Kettering Cancer Center and the value framework by a working committee of The American Society for Clinical Oncology, the National Comprehensive Cancer Network (NCCN) has announced the development of another “price” calculator that will help stakeholders assess the relative “value” of available options.
The NCCN tool includes 5 measures to be scored: price, drug efficacy, drug safety, quality of clinical data, and consistency of clinical data. The score will guide prescribing physicians to make more informed decisions and can help avoid bias. To be launched in mid-October this year, the tool, which currently includes data for 2 cancer types (multiple myeloma and chronic myeloid leukemia), will eventually be a part of electronic healthcare technology systems used in hospitals such as IBM’s Watson. Comparator data for other tumor types is expected to be available by the end of 2016.
Are the drug manufacturers disgruntled by the current wave of resistance against drug pricing? The argument is that pharma needs a return on their investment, which is years of research and multiple failures before a target molecule is identified and successfully developed into a product. According to Dr Gregory P. Rossi, vice president for Payer and Real World Evidence at AstraZeneca, technical risk, time, and market assumptions all impact investment decisions. So considering these investment costs, treatments directed at small patient populations require higher drug prices to gain returns.
"A company that has an effective drug that's appropriately priced should welcome these blocks," said Dr Robert Carlson, NCCN's chief executive. If a drug is overpriced, "that's very important information for everybody."
Health plans and pharmacy benefit managers, meanwhile, have also been more vigilant, with preferred lists of medications and tiered formularies. Patients, too, are more involved with understanding the cost and quality of care provided by a specific drug. But working in isolated pockets may not be the best model to achieve measurable outcomes. What we need is for the various factions to come to the table to achieve the common goal of better care at “reasonable” costs.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More